Telehealth in 2026 operates in a regulatory environment that's simultaneously more permissive than pre-pandemic norms and more uncertain than anyone would like. The pandemic-era flexibilities that expanded virtual care access have been extended — but not made permanent. Understanding where the rules stand helps both patients and providers navigate what's actually allowed.
The DEA telehealth flexibilities
The most significant regulatory question concerns controlled substances. Under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, a prescriber was required to conduct at least one in-person evaluation before prescribing controlled substances via telehealth. During the COVID-19 emergency, this requirement was waived. That waiver has been extended four times — most recently through December 31, 2026.
This means that through the end of 2026, DEA-registered practitioners can prescribe Schedule II–V controlled substances via audio-video telehealth encounters without ever having seen the patient in person. In 2024, more than 7 million controlled substance prescriptions — 16% of all such prescriptions — were issued via telehealth without a prior in-person visit.
What happens after December 2026?
Nobody knows with certainty. The DEA and HHS are working on permanent regulations, including a proposed Special Registration for Telemedicine that would create a formal pathway for telehealth prescribing of controlled substances. But the Trump administration has not finalized the proposed rules developed under the Biden administration, and the timeline remains unclear. The worst-case scenario — a sudden return to pre-pandemic restrictions, called the "telemedicine cliff" — would disrupt care for millions of patients.
Non-controlled substance telehealth
For non-controlled medications — which include most of what telehealth platforms prescribe (GLP-1s, finasteride, minoxidil, PDE5 inhibitors, SSRIs, statins, and more) — there is no federal in-person requirement. Prescribers must meet the standard of care, maintain proper documentation, and comply with state-specific telehealth laws, but there is no DEA involvement and no special telemedicine registration required.
State-level variation
Even with federal flexibilities in place, state laws vary. Some states have passed permanent telehealth parity laws that require insurers to cover telehealth visits at the same rates as in-person care. Others have more restrictive prescribing rules, particularly around controlled substances. Prescribers practicing across state lines must hold licenses in each state where they treat patients, and some states impose additional requirements such as establishing a provider-patient relationship via video (not just questionnaire) before prescribing certain medications.
Medicare telehealth policy
Medicare telehealth coverage saw a significant setback in September 2025, when the lapse of certain Medicare telehealth flexibilities resulted in a 24% drop in fee-for-service telehealth visits. Some flexibilities have been restored, but the coverage landscape remains in flux. Medicare beneficiaries should verify telehealth coverage with their specific plan before scheduling visits.
Our Assessment
The 2026 telehealth regulatory environment is functional but temporary. The controlled substance flexibilities expire December 31, 2026. For non-controlled medications — which include most telehealth prescriptions — federal regulation is more stable. The biggest risk is the absence of a permanent federal framework: patients and providers are building long-term care relationships on temporary rules. Watch for permanent rulemaking by the DEA and CMS as the year progresses.